Table 1: Summary of demographic information for established RA patient cohort receiving TNF inhibitors and response with respect to health assessment questionnaire disability index (HAQ-DI) and pain.

Established RA TNFi Treatment Rheumatoid Factor Positive (RF+) Rheumatoid Factor Negative (RF-) P Value
Total N with RF results available (238)(% of included patients) 178 (75%) 60 (25%)  
% Female 82% 72% 0.7
Age (SD) 57    (14) 56    (12) 0.6
Disease duration {years} (SD) 12      (8)   9      (8) 0.017
N with available paired HAQ-DI results at 1 year# (% of included patients) N included 128   90 (70%) 38 (30%)  
Baseline HAQ-DI (SD)(0=3) prior to TNFi 1.44    (0.63) 1.41    (0.63) 0.8
HAQ-DI change Baseline to Year 1 -0.356 (0.60) -0.126 (0.54) 0.04
N with available paired Pain results at 1 year# (% of included patients) N included 109   77 (71%) 32 (29%)  
Baseline PAIN (SD)(0-3) 1.92    (0.67) 1.93    (0.67) 0.9
PAIN change Baseline to Year 1 -0.725 (0.86) -0.332 (0.82) 0.03
Mean treatment duration for first TNFi {Years} (SD)N=238 2.8       (2.0) 2.3       (1.6) 0.1
Proportion of patients still on same TNFi after at last follow up from the included 238 patients 68% 62% 0.5

Note of 340 identified patients, only 238 had some data available for analysis. SD = Standard Deviation; Age and Disease Duration is shown in Years; p-Value with significance at <0.05, #Only the patients with available data compose the N for each result. The demographics (age, sex, disease duration, baseline HAQ-DI, baseline pain) of the patients with available data was not significantly different from those with incomplete data.